Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2022 Earnings Conference Call August 15, 2022 8:00 AM ET

Company Participants

Paul Davis - Head of Communications

Matt Gline - CEO

Conference Call Participants

David Risinger - SVB Securities

Dennis Ding - Jefferies

Neena Bitritto-Garg - Citi

Louise Chen - Cantor Fitzgerald

Douglas Tsao - HC Wainwright

Corinne Jenkins - Goldman Sachs

Brendan Smith - Cowen

Alexander Xenakis - Truist Securities

Operator

Good day, and thank you for standing by. Welcome to the Roivant 1Q 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Paul Davis, Head of Communication. Please go ahead.

Paul Davis

Good morning, and thank you for joining today's call to discuss Roivant's financial results for the quarter ended June 30, 2022. I'm Paul Davis, Head of Communications at Roivant. Presenting today, we have Matt Gline, our Chief Executive Officer. For those dialing in via conference call you can find the slide being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along.

I would like to remind you that we'll be making certain forward-looking statements during today's presentation that reflect our current views and expectations, including those related to our financial performance and the potential attributes of our products and product candidates. We strongly encourage you to review the information that we filed with the SEC, including the earnings release and Form 10-Q filed this morning for more information regarding these forward-looking statements and related risks and uncertainties. We'll begin with Matt Gline, who will review key business updates across Roivant in advance, and provide a financial update. We'll end the call with a Q&A session.

With that, I'll turn it over to Matt.

Matt Gline

Thank you, Paul, and good morning, everybody, and thank you for joining our first quarter earnings call. Today's call will be a little bit shorter than usual because we last got together about six weeks ago, when we presented our year-end results.

So I'll begin on Page 4 and I'll take you through some of the key highlights of the business today and then we'll make some time Q&A. So as a reminder, we're excited about where we are at the end of our first quarter this year, with obviously a number of important attributes, including the ongoing commercial launch of VTAMA, which we will spend a little bit of time on this morning, that is backed by a broad clinical stage pipeline, including multiple pivotal and registrational study is currently ongoing.